Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys



Rating:

Share or cite this content

Citations should be made in the following way:
V. Kahlmann (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), C. Broos (Rotterdam, Netherlands), J. In ’T Veen (Rotterdam, Netherlands), M. Overbeek (The Hague, Netherlands), M. Grootenboers (Breda, Netherlands), R. Heller (Rotterdam, Netherlands), R. Mostard (Heerlen, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands). Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis. 3985

Member's Comments

No comment yet.

Related content which might interest you: The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Follow-up of the patients with newly diagnosed sarcoidosis treated with oral corticosteroids. Features associated with chronic sarcoidosis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 High-doses glucocorticosteroid treatment in sarcoidosis patients Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007 Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005 Rituximab in the treatment of refractory pulmonary sarcoidosis Source: Eur Respir J 2014; 43: 1525-1528 Year: 2014 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003 Long-term lung function follow-up in patients diagnosed and treated for pulmonary tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Long-term follow-up of patients with pulmonary sarcoidosis Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients Source: Eur Respir Rev 2013; 22: 93-95 Year: 2013 The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Pentoxifylline and reduced doses of steroids combination in pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007